<p><strong>诺和诺德</strong>(NVO 6.40%) 的股价在周三上午 11:30 上涨了 6%。这一变动是在 <strong>辉瑞</strong> 与特朗普政府达成协议后出现的，市场对其他制药公司，包括诺和诺德，能够达成类似协议的希望也随之上升。</p>
<h2>特朗普的制药关税</h2>
<p>特朗普政府旨在将制药制造业带回美国。总统唐纳德·特朗普在 Truth Social 上的一条帖子中威胁对 “任何品牌或专利药品” 征收 100% 的关税，这一威胁针对的是那些在国外生产药品并进口到美国销售的制药公司，无论是国内公司还是其他公司。</p>
<p>然而，辉瑞表示，今天的协议给予该公司三年的宽限期，条件是它在美国的制造投资增加。该公司表示，它自愿 “同意实施措施，以确保美国人获得与其他发达国家相当的药品价格。”</p>
<h2>对诺和诺德投资者的意义</h2>
<p>尽管诺和诺德是一家欧洲公司，但它在北卡罗来纳州有相当大的制造基地，并正在该州进行 41 亿美元的投资以扩大其制造能力。此外，商务部长霍华德·卢特尼克表示，政府在与制药公司完成谈判之前不会征收关税。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzU4MTkvcGhhcm1hY3ktcGhhcm1hY2lzdC1kcnVnLW1lZGljaW5lLXByZXNjcmlwdGlvbi5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzU4MTkvcGhhcm1hY3ktcGhhcm1hY2lzdC1kcnVnLW1lZGljaW5lLXByZXNjcmlwdGlvbi5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<p>这一消息提高了诺和诺德能够达成类似协议的希望，而此时该公司正希望获得批准以市场销售一种口服减肥药——这是 2025 年购买该股票的一个重要理由。</p>

诺和诺德公司

<p>诺和诺德公司的股票在辉瑞与特朗普政府达成协议后上涨了 6%，这提高了其他制药公司获得类似条款的希望。该协议为辉瑞提供了三年的关税宽限期，前提是美国制造业的增加。诺和诺德在北卡罗来纳州有重要业务，并计划进行 41 亿美元的扩张，可能会从这些发展中受益，特别是在其寻求口服减肥药的批准时</p>

<p>Shares in <strong>Novo Nordisk</strong>(NVO 6.40%) were up 6% by 11:30 a.m. on Wednesday. The move comes after <strong>Pfizer</strong>'s agreement with the Trump administration raised hopes that other pharmaceutical companies, including Novo Nordisk, could reach similar terms.</p>
<div class="lb-trans"><p><strong>诺和诺德</strong>(NVO 6.40%) 的股价在周三上午 11:30 上涨了 6%。这一变动是在 <strong>辉瑞</strong> 与特朗普政府达成协议后出现的，市场对其他制药公司，包括诺和诺德，能够达成类似协议的希望也随之上升。</p>
</div><h2>Trump's pharmaceutical tariffs</h2>
<div class="lb-trans"><h2>特朗普的制药关税</h2>
</div><p>The administration aims to bring pharmaceutical manufacturing back to the U.S. President Donald Trump's threat of 100% tariffs &#34;on any branded or patented Pharmaceutical Product,&#34; which he made in a Truth Social post, is targeted at pharmaceutical companies, domestic or otherwise, that manufacture drugs abroad and import them for sale in the U.S.</p>
<div class="lb-trans"><p>特朗普政府旨在将制药制造业带回美国。总统唐纳德·特朗普在 Truth Social 上的一条帖子中威胁对 “任何品牌或专利药品” 征收 100% 的关税，这一威胁针对的是那些在国外生产药品并进口到美国销售的制药公司，无论是国内公司还是其他公司。</p>
</div><p>However, Pfizer said that today's agreement grants the company a three-year grace period before the tariffs are applied, on the condition that it invests more in manufacturing in the U.S. The company said that it voluntarily &#34;agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries.&#34;</p>
<div class="lb-trans"><p>然而，辉瑞表示，今天的协议给予该公司三年的宽限期，条件是它在美国的制造投资增加。该公司表示，它自愿 “同意实施措施，以确保美国人获得与其他发达国家相当的药品价格。”</p>
</div><h2>What it means to Novo Nordisk investors</h2>
<div class="lb-trans"><h2>对诺和诺德投资者的意义</h2>
</div><p>Although Novo Nordisk is a European company, it has a substantial manufacturing presence in North Carolina and is making a $4.1 billion investment to expand its manufacturing in the state. Furthermore, Commerce Secretary Howard Lutnick has stated that the administration will not impose the tariffs until negotiations with pharmaceutical companies are completed.</p>
<div class="lb-trans"><p>尽管诺和诺德是一家欧洲公司，但它在北卡罗来纳州有相当大的制造基地，并正在该州进行 41 亿美元的投资以扩大其制造能力。此外，商务部长霍华德·卢特尼克表示，政府在与制药公司完成谈判之前不会征收关税。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzU4MTkvcGhhcm1hY3ktcGhhcm1hY2lzdC1kcnVnLW1lZGljaW5lLXByZXNjcmlwdGlvbi5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F835819%2Fpharmacy-pharmacist-drug-medicine-prescription.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>The news raises hopes that Novo Nordisk could reach a similar deal, and it comes at a time when the company is hoping to receive approval to market an oral weight loss drug -- one great reason to buy the stock in 2025.</p>
<div class="lb-trans"><p>这一消息提高了诺和诺德能够达成类似协议的希望，而此时该公司正希望获得批准以市场销售一种口服减肥药——这是 2025 年购买该股票的一个重要理由。</p>
</div>

为什么诺和诺德公司的股票今天有所上涨